{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:50:50Z","timestamp":1767340250415,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clml.2019.03.021","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:03:57Z","timestamp":1553861037000},"page":"e513-e520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-8966","authenticated-orcid":false,"given":"Abu-Sayeef","family":"Mirza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai R.","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-0489","authenticated-orcid":false,"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adharsh","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-6694","authenticated-orcid":false,"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.021_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","article-title":"Primary effusion lymphoma","volume":"12","author":"Chen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.03.021_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/dc.20432","article-title":"Serous effusions in malignant lymphomas: a review","volume":"34","author":"Das","year":"2006","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.clml.2019.03.021_bib3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00000478-200210000-00014","article-title":"Primary effusion lymphoma with subsequent development of a small bowel mass in an HIV-seropositive patient: a case report and literature review","volume":"26","author":"Huang","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2019.03.021_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1128\/JVI.79.2.1244-1251.2005","article-title":"Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association","volume":"79","author":"Fan","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2019.03.021_bib5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/hon.2372","article-title":"Clinical characteristics and survival outcome of primary effusion lymphoma: a review of 105 patients","volume":"35","author":"El-Fattah","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.021_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajh.10341","article-title":"Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma","volume":"73","author":"Boulanger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.021_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.24251","article-title":"Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution","volume":"91","author":"Guillet","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl","key":"10.1016\/j.clml.2019.03.021_bib9","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.clml.2016.02.018","article-title":"Management and outcomes of HIV-associated primary effusion lymphoma: a single center experience","volume":"16","author":"Gupta","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.03.021_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1532\/IJH97.A30510","article-title":"Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus","volume":"83","author":"Won","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.03.021_bib11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.03.021_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.021_bib13","first-page":"372","article-title":"Use of cidofovir for the treatment of HIV-negative human herpes virus-8 associated primary effusion lymphoma","volume":"8","author":"Moyo","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.021_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/00325481.2017.1286925","article-title":"KSHV-associated extracavitary primary effusion lymphoma in an HIV seronegative patient: a case report and review of the literature","volume":"129","author":"Ibrahim","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clml.2019.03.021_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4132\/KoreanJPathol.2014.48.2.81","article-title":"Current concepts in primary effusion lymphoma and other effusion-based lymphomas","volume":"48","author":"Kim","year":"2014","journal-title":"Korean J Pathol"},{"key":"10.1016\/j.clml.2019.03.021_bib16","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/bcj.2014.6","article-title":"Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature","volume":"4","author":"Antar","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.021_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.anndiagpath.2012.03.004","article-title":"Extracavitary\/solid variant of primary effusion lymphoma","volume":"16","author":"Kim","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clml.2019.03.021_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4103\/0377-4929.168851","article-title":"Extracavitary primary effusion lymphoma: a case report from India","volume":"58","author":"Sampath","year":"2015","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.clml.2019.03.021_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1525-1578(10)60004-9","article-title":"Kaposi's sarcoma-associated herpesvirus\/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma","volume":"7","author":"Carbone","year":"2005","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2019.03.021_bib20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/PAS.0b013e31825b38ec","article-title":"Extracavitary KSHV-associated large B-cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases","volume":"36","author":"Pan","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2019.03.021_bib21","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2013-01-481713","article-title":"CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma","volume":"122","author":"Bhatt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.021_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/17474086.2016.1130615","article-title":"Clinical management of HIV-associated hematologic malignancies","volume":"9","author":"Wang","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2019.03.021_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5582\/irdr.2014.01010","article-title":"Current status of treatment for primary effusion lymphoma","volume":"3","author":"Okada","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.clml.2019.03.021_bib24","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/AAC.41.12.2754","article-title":"Antiviral drug susceptibility of human herpesvirus 8","volume":"41","author":"Neyts","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clml.2019.03.021_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MCP.0000000000000384","article-title":"Primary effusion lymphoma: current concepts and management","volume":"23","author":"Arora","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.clml.2019.03.021_bib26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1806295","article-title":"Daratumumab in primary effusion lymphoma","volume":"379","author":"Shah","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.021_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/108729104322802498","article-title":"Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review","volume":"18","author":"Waddington","year":"2004","journal-title":"AIDS Patient Care STDS"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018317464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018317464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:44Z","timestamp":1761870764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018317464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2152265018317464"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}